Volume 14 Supplement 1
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Meeting abstracts
Edited by John C Burnett Jr, Franz Hofmann, Kazuwa Nakao, Harald HHW Schmidt and Johannes-Peter Stasch
Publication of this supplement has been fully funded by Bayer Pharma AG. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications. Go to conference site.
Erfurt, Germany28-30 June 2013
Page 1 of 3
-
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O1
-
Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O2 -
Abstract not submitted for publication
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O3 -
Lessons from tissue-specific KO of CNP/GC-B system - everlasting challenge to clinical application
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O4 -
What have genome-wide association studies taught us about cGMP and blood pressure regulation?
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O5 -
Genetic variants in guanylyl cyclase and phoshodiesterase affecting coronary disease risk
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O6 -
Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O7 -
Genetic modifiers of hypertension in sGC-deficient mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O8 -
Pulmonary vascular adaptation to high-altitude living
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O9 -
MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O10 -
cGMP kinase: past, presence and future
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O11 -
Conformational changes involved in sGC activation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O12 -
A twenty year journey to understand how ATP activates guanylyl cyclase A and B
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O13 -
Soluble guanylate cyclase crystal clear: 1stcrystal structure of the wild-type human heterodimeric sGC catalytic domains and implications for activity
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O14 -
Crystal structures of human soluble guanylate cyclase catalytic domains: promiscuity of the dimer interface and a potential allosteric site
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O15 -
Structures of human PKG reveal cGMP-selectived activation mechanisms
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O16 -
Targeting native and apo-sGC
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O17 -
Mechanisms driving heme insertion into apo-sGC during its maturation in cells
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O18 -
Redox signalling by protein kinase G Iα in cardiovascular physiology and pathology
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O19 -
New mechanisms of normoxic and hypoxic cGMP signalling mediated by the nitrite anion
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O20 -
Thiol-redox proteins interact with soluble guanylyl cyclase and modulate its activity
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O21 -
Chronic beta-adrenergic blockade prevents volume overload-induced re-localization and oxidation of soluble guanylyl cyclase
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O22 -
Elementary Ca2+signals through endothelial TRPV4 channels regulate vascular function
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O23 -
Natriuretic peptides and fat metabolism
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O24 -
Role of cGMP in fat and metabolism
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O25 -
Non-genomic thyroid hormone signaling through NO/cGMP/PKGII
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O26 -
cGMP-Prkg1 signaling PDE5 inhibition shelter cochlear hair cells and hearing function
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O27 -
GUCY2C at the intersection of obesity and colorectal cancer
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O28 -
Cell type-specific knock out models to unravel NO/cGMP signaling in smooth muscle
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O29 -
Interstitial cells of Cajal link excitatory and nitrergic inhibitory neurotransmission with slow-wave activity in the intestine
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O30 -
cGMP-dependent kinase 2, Na+/H+ regulatory factor 2, and Na+/H+ exchanger isoform 3 assemble within lipid rafts in murine small intestinal brush border membrane
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O31 -
NO-H2S interactions involve cGMP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O32 -
67-kDa laminin receptor and cGMP induced cancer-selective apoptosis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O33 -
A novel physiological significance of natriuretic peptides in cancer metastasis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O34 -
Dual actions of ANP on endothelial permeability
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O35 -
Pseudomonas aeruginosaExoY, a cyclic GMP- and cyclic UMP-generating nucleotidyl cyclase
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O36 -
Nitric oxide regulated cyclic di-GMP signaling
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O37 -
Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O38 -
Neutral endopeptidase inhibitors SOL-1 and candoxatril counteract kidney fibrosis by reducing myofibroblast formation in mouse UUO model
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P1 -
Hydroxyurea reduces leukocyte interactions with the vessel wall in a haemolytic mouse model via a possible NO/cGMP-mediated effect
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P2 -
Effect of nitrite treatment on endothelial nitric oxide synthase in human left ventricle biopsy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P3 -
A possible crosstalk between cGMP pathway and Activin receptor-like kinase 7 (Alk7) in adipocytes
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P4 -
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P5 -
Effects of omeprazole and AlOH/MgOH on riociguat absorption
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P6 -
Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P7 -
Role of NO-sensitive guanylyl cyclase in angiogenesis and arteriogenesis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P8 -
NO-cGMP signalling and cancer therapy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P9 -
Identification of protein kinase G I alpha interacting proteins as potential targets to prevent cardiac remodeling
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P10 -
G-protein signaling modulator 1 is a modifier of sGC-dependent vascular response
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P11 -
Identification and quantitation of 2´,3´-cGMP in murine tissues
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P12
Annual Journal Metrics
-
Citation Impact
2.605 - 2-year Impact Factor (2021)
2.943 - 5-year Impact Factor (2021)
0.953 - SNIP (Source Normalized Impact per Paper)
0.497 - SJR (SCImago Journal Rank)Speed
42 days to first decision for all manuscripts (Median)
59 days to first decision for reviewed manuscripts only (Median)Usage
588,461 Downloads (2021)
402 Altmetric mentions (2021)
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication